Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

December 31, 2025

Conditions
Differentiated Thyroid CancerGender
Interventions
DRUG

Lenvatinib

Patients will be treated by lenvatinib as recommended by good clinical practice

Trial Locations (1)

00144

RECRUITING

Regina Elena National Cancer Institute, Rome

All Listed Sponsors
collaborator

University of Turin, Italy

OTHER

collaborator

University of Roma La Sapienza

OTHER

collaborator

University of Siena

OTHER

collaborator

University of Pisa

OTHER

collaborator

Istituto Oncologico Veneto IRCCS

OTHER

collaborator

University of Catania

OTHER

collaborator

Istituto Auxologico Italiano

OTHER

lead

Regina Elena Cancer Institute

OTHER